Previous close | 0.6503 |
Open | 0.6501 |
Bid | 0.6669 x 200 |
Ask | 0.6728 x 200 |
Day's range | 0.6500 - 0.6849 |
52-week range | 0.1990 - 3.0150 |
Volume | |
Avg. volume | 1,754,793 |
Market cap | 79.971M |
Beta (5Y monthly) | 0.72 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 8.20% and 73.91%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Key Insights Institutions' substantial holdings in Atara Biotherapeutics implies that they have significant influence...
Renowned value investor Seth Klarman (Trades, Portfolio), through The Baupost Group, has recently divested the firm's entire stake in Atara Biotherapeutics Inc (NASDAQ:ATRA). This move has had a noticeable impact on Klarman's portfolio, reducing its exposure to the healthcare sector.